BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Antitope Announces EpiScreen Collaboration with Abraxis BioScience, Inc.


9/29/2010 1:27:33 PM

September 29, 2010 -- Antitope Ltd., Cambridge UK (“Antitope”) today announced a they will be providing immunogenicity evaluation services for Abraxis BioScience LLC, Los Angeles, USA ("Abraxis") whereby Antitope will apply its proprietary EpiScreenTM technology to analyse the immunogenicity potential of selected therapeutic proteins developed by Abraxis.

“We are delighted to be working with Abraxis whose innovative discovery programmes and technologies are uncovering exciting new drug candidates for further investigation” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "The EpiScreenTM technology will enable us to assist Abraxis by providing a pre-clinical assessment of the immunogenicity of their therapeutics in order to select leads with low immunogenicity potential."

About Antitope Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For further information on Antitope visit;

http://www.antitope.co.uk or contact: Dr. Neil Butt Business Development Director, Antitope Ltd. Tel: +44 (0)1223 496190

About Abraxis

Abraxis BioScience (NASDAQ code AbII) is a fully integrated biotechnology company dedicated to delivering rogressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its proprietary tumor targeting system known as the nab™ Technology platform. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them.

For further information on Abraxis contact:

Corporate Communications Abraxis BioScience 11755 Wilshire Blvd. Suite 2000 Los Angeles, CA 90025 United States


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->